
Non-Sponsored Content
Abemaciclib in combination with fulvestrant FDA approved for HR+, HER2- advanced or metastatic breast cancer progressing following endocrine therapy
By: News Feed | Last updated: 28th September 2017 | In: US FDA Onc\Haem Approvals
Article Keywords
abemaciclib, AstraZeneca, AZ, CDK46, Eli Lilly, Faslodex, FDA, fulvestrant, HER2, HR, Verzenio
On 28 September 2017, the FDA approved abemaciclib (Verzenio®, Eli Lilly and Company) in combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.
YOU MAY ALSO LIKE




































































Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients












































































































© Copyright 2018 MediPaper Medical Communications Ltd.
Leave a Reply
Want to join the discussion?Feel free to contribute!